Natural products - The future scaffolds for novel antibiotics?

Biochemical Pharmacology

Volumn 71, Issue 7, 2006, Pages 919-929

  Butler, Mark S ^a   Buss, Antony D ^a  

^a MerLion Pharmaceuticals Pte Ltd   (Singapore)

Author keywords

Antibacterial; Antibiotic; Assay; Clinical trial; Natural product; Template

Indexed keywords

ACTINONIN; ANSAMYCIN DERIVATIVE; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CAPRAZAMYCIN; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CETHROMYCIN; ECO 0501; FAROPENEM DALOXATE; GE 23077; GLYCOPEPTIDE; MACROLIDE; MANNOPEPTIMYCIN; ME 1211; MURAYMYCIN; N (5 FLUORO 1 OXIDO 2 PYRIDINYL) 1 [2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANOYL]PROLINAMIDE; NATURAL PRODUCT; NOCATHIACIN; OPT 80; PAR 101; PLEUROMUTILIN; PTK 0796; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAMOPLANIN; RIFALAZIL; RWJ 442831; SB 275833; STREPTOGRAMIN; TEBIPENEM PIVOXIL; TELAVANCIN; TELEVANCIN; TETRACYCLINE DERIVATIVE; TIACUMICIN B; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; BACTERIAL INFECTION; CLINICAL TRIAL; DIARRHEA; DRUG ISOLATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SENSITIVITY; DRUG STRUCTURE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN INFECTION; TREATMENT OUTCOME;

EID: 33644535147     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.10.012     Document Type: Article

References (100)

1. W. Sneader Drug discovery: a history 2005 John Wiley & Sons Chichester
2. D.J. Newman, G.M. Cragg, and K.M. Snader The influence of natural products upon drug discovery Nat Prod Rep 17 3 2000 215 234
3. J. Drews Drug discovery: a historical perspective Science 287 5460 2000 1960 1964
4. C.T. Walsh, and G. Wright Introduction: antibiotic resistance Chem Rev 105 2 2005 391 393
5. Finch RG, Greenwood D, Norrby SR, Whitley RJ, editors. Antibiotic and chemotherapy: anti-infective agents and their use in therapy. 8th ed. New York: Churchill Livingstone; 2003.
6. Graul AI, Prous JR. The year's new drugs. Drug News Perspect 2005;18(1):21-36 (and previous reviews in this series).
7. Hegde S, Carter J. To Market, To Market-2003. In: Doherty AM, editor. Annual reports in medicinal chemistry. Amsterdam: Academic Press; 2003. p. 335-68 (and previous reviews in this series).
8. FDA approves Tygacil, first-in-class antibiotic. Wyeth Press Release; 2005. Available at http://www.wyeth.com.
9. Shionogi receives approval to manufacture and market carbapenem antibiotic products "Finibax 0.25g IV Solution" and "Finibax Intradermal Test" (doripenem Hydrate). Shionogi & Co. Press Release; 2005. Available at http://www.shionogi.co.jp.
10. M.J. Stone, and D.H. Williams On the evolution of functional secondary metabolites (natural products) Mol Microbiol 6 1 1992 29 34
11. M.S. Butler The role of natural product chemistry in drug discovery J Nat Prod 67 12 2004 2141 2153
12. F.E. Koehn, and G.T. Carter The evolving role of natural products in drug discovery Nat Rev Drug Discov 4 3 2005 206 220
13. M.S. Butler Natural products to drugs: natural product-derived compounds in clinical trials Nat Prod Rep 22 2 2005 162 195
14. M.N. Alekshun New advances in antibiotic development and discovery Expert Opin Investig Drugs 14 2 2005 117 134
15. P.C. Appelbaum, and M.R. Jacobs Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria Curr Opin Microbiol 8 5 2005 510 517
16. B.L. Rogers Bacterial targets to antimicrobial leads and development candidates Curr Opin Drug Discov Dev 7 2 2004 211 222
17. K. Bush, M. Macielag, and M. Weidner-Wells Taking inventory: antibacterial agents currently at or beyond phase 1 Curr Opin Microbiol 7 5 2004 466 476
18. Bad Bugs, No Drugs. Infectious Diseases Society of America, VA: Alexandria; 2004. Available at http://www.idsociety.org/.
19. F.M. Walsh, and S.G. Amyes Microbiology and drug resistance mechanisms of fully resistant pathogens Curr Opin Microbiol 7 5 2004 439 444
20. J.F. Barrett Can biotech deliver new antibiotics? Curr Opin Microbiol 8 5 2005 498 503
21. K.M. Overbye, and J.F. Barrett Antibiotics: where did we go wrong? Drug Discov Today 10 1 2005 45 52
22. C. Walsh Where will new antibiotics come from? Nat Rev Microbiol 1 1 2003 65 70
23. A. Coates, Y. Hu, R. Bax, and C. Page The future challenges facing the development of new antimicrobial drugs Nat Rev Drug Discov 1 11 2002 895 910
24. S.J. Projan, and D.M. Shlaes Antibacterial drug discovery: is it all downhill from here? Clin Microbiol Infect 10 Suppl 4 2004 18 22
25. S.J. Projan Why is big pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 6 5 2003 427 430
26. R. Jain, D. Chen, R.J. White, D.V. Patel, and Z. Yuan Bacterial peptide deformylase inhibitors: a new class of antibacterial agents Curr Med Chem 12 14 2005 1607 1621
27. K.W. Johnson, D. Lofland, and H.E. Moser PDF inhibitors: an emerging class of antibacterial drugs Curr Drug Targets Infect Disord 5 1 2005 39 52
28. K.T. Nguyen, X. Hu, C. Colton, R. Chakrabarti, M.X. Zhu, and D. Pei Characterization of a human peptide deformylase: implications for antibacterial drug design Biochemistry 42 33 2003 9952 9958
29. D.Z. Chen, D.V. Patel, C.J. Hackbarth, W. Wang, G. Dreyer, and D.C. Young Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor Biochemistry 39 6 2000 1256 1262
30. R. Jain, A. Sundram, S. Lopez, G. Neckermann, C. Wu, and C. Hackbarth α-Substituted hydroxamic acids as novel bacterial deformylase inhibitor-based antibacterial agents Bioorg Med Chem Lett 13 23 2003 4223 4228
31. D. Chen, C. Hackbarth, Z.J. Ni, C. Wu, W. Wang, and R. Jain Peptide deformylase inhibitors as antibacterial agents: identification of VRC3375, a proline-3-alkylsuccinyl hydroxamate derivative, by using an integrated combinatorial and medicinal chemistry approach Antimicrob Agents Chemother 48 1 2004 250 261
32. C.J. Hackbarth, D.Z. Chen, J.G. Lewis, K. Clark, J.B. Mangold, and J.A. Cramer N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity Antimicrob Agents Chemother 46 9 2002 2752 2764
33. Molecule of the month. LBM-415. Drug News Perspect 2005;18(1):46.
34. J.M. Bell, J.D. Turnidge, M. Inoue, S. Kohno, Y. Hirakata, and Y. Ono Activity of a peptide deformylase inhibitor LBM415 (NVP PDF-713) tested against recent clinical isolates from Japan J Antimicrob Chemother 55 2 2005 276 278
35. T.R. Fritsche, H.S. Sader, R. Cleeland, and R.N. Jones Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance Antimicrob Agents Chemother 49 4 2005 1468 1476
36. J.M. Clements, R.P. Beckett, A. Brown, G. Catlin, M. Lobell, and S. Palan Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor Antimicrob Agents Chemother 45 2 2001 563 570
37. P.S. Margolis, C.J. Hackbarth, D.C. Young, W. Wang, D. Chen, and Z. Yuan Peptide deformylase in Staphylococcus aureus: resistance to inhibition is mediated by mutations in the formyltransferase gene Antimicrob Agents Chemother 44 7 2000 1825 1831
38. P. Margolis, C. Hackbarth, S. Lopez, M. Maniar, W. Wang, and Z. Yuan Resistance of Streptococcus pneumoniae to deformylase inhibitors is due to mutations in defB Antimicrob Agents Chemother 45 9 2001 2432 2435
39. C.R. Dean, S. Narayan, D.M. Daigle, J.L. Dzink-Fox, X. Puyang, and K.R. Bracken Role of the AcrAB-TolC efflux pump in determining susceptibility of Haemophilus influenzae to the novel peptide deformylase inhibitor LBM415 Antimicrob Agents Chemother 49 8 2005 3129 3135
40. F. Schlunzen, E. Pyetan, P. Fucini, A. Yonath, and J.M. Harms Inhibition of peptide bond formation by pleuromutilins: the structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin Mol Microbiol 54 5 2004 1287 1294
41. GlaxoSmithKline. GSK Pipeline. Information available at http://science.gsk.com/pipeline/.
42. GlaxoSmithKline. Results announcement for the second quarter 2005; 2005. Available at http://www.gsk.com/financial/reports/gsk_q22005/q22005.pdf.
43. WHO Drug Information 2005;19(1):69-100. Available at http://www.who.int/ druginformation/.
44. D.G. McCafferty, P. Cudic, B.A. Frankel, S. Barkallah, R.G. Kruger, and W. Li Chemistry and biology of the ramoplanin family of peptide antibiotics Biopolymers 66 4 2002 261 284
45. S. Walker, L. Chen, Y. Hu, Y. Rew, D. Shin, and D.L. Boger Chemistry and biology of ramoplanin: a lipoglycodepsipeptide with potent antibiotic activity Chem Rev 105 2 2005 449 476
46. D.K. Farver, D.D. Hedge, and S.C. Lee Ramoplanin: a lipoglycodepsipeptide antibiotic Ann Pharmacother 39 5 2005 863 868
47. Oscient Pharmaceuticals. Press release 2; 2005. Available at http://www.oscient.com/.
48. J.E. Hochlowski, S.J. Swanson, L.M. Ranfranz, D.N. Whittern, A.M. Buko, and J.B. McAlpine Tiacumicins, a novel complex of 18-membered macrolides. Part II. Isolation and structure determination J Antibiot (Tokyo) 40 5 1987 575 588
49. R.J. Theriault, J.P. Karwowski, M. Jackson, R.L. Girolami, G.N. Sunga, and C.M. Vojtko Tiacumicins, a novel complex of 18-membered macrolide antibiotics. Part I. Taxonomy, fermentation and antibacterial activity J Antibiot (Tokyo) 40 5 1987 567 574
50. C. Coronelli, R.J. White, G.C. Lancini, and F. Parenti Lipiarmycin, a new antibiotic from Actinoplanes. Part II. Isolation, chemical, biological and biochemical characterization J Antibiot (Tokyo) 28 4 1975 253 259
51. S. Omura, N. Imamura, R. Oiwa, H. Kuga, R. Iwata, and R. Masuma Clostomicins, new antibiotics produced by Micromonospora echinospora subsp. armeniaca subsp. nov. I. Production, isolation, and physico-chemical and biological properties J Antibiot (Tokyo) 39 10 1986 1407 1412
52. S. Sergio, G. Pirali, R. White, and F. Parenti Lipiarmycin, a new antibiotic from Actinoplanes III. Mechanism of action J Antibiot (Tokyo) 28 7 1975 543 549
53. R.N. Swanson, D.J. Hardy, N.L. Shipkowitz, C.W. Hanson, N.C. Ramer, and P.B. Fernandes In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile Antimicrob Agents Chemother 35 6 1991 1108 1111
54. G. Ackermann, B. Loffler, D. Adler, and A.C. Rodloff In vitro activity of OPT-80 against Clostridium difficile Antimicrob Agents Chemother 48 6 2004 2280 2282
55. K.L. Credito, and P.C. Appelbaum Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species Antimicrob Agents Chemother 48 11 2004 4430 4434
56. S.M. Finegold, D. Molitoris, M.L. Vaisanen, Y. Song, C. Liu, and M. Bolanos In vitro activities of OPT-80 and comparator drugs against intestinal bacteria Antimicrob Agents Chemother 48 12 2004 4898 4902
57. Optimer Pharmaceuticals. Press release; 2005. Available at http://www.optimerpharma.com/.
58. Par Pharmaceutical. Press release; 2005. Available at http://www.parpharm.com/.
59. A. Höltzel, D.G. Schmid, G.J. Nicholson, S. Stevanovic, J. Schimana, and K. Gebhardt Arylomycins A and B, new biaryl-bridged lipopeptide antibiotics produced by Streptomyces sp. Tü 6075. Part II. Structure elucidation J Antibiot (Tokyo) 55 6 2002 571 577
60. J. Schimana, K. Gebhardt, A. Höltzel, D.G. Schmid, R. Süssmuth, and J. Müller Arylomycins A and B, new biaryl-bridged lipopeptide antibiotics produced by Streptomyces sp. Tü 6075. Part I. Taxonomy, fermentation, isolation and biological activities J Antibiot (Tokyo) 55 6 2002 565 570
61. M. Paetzel, J.J. Goodall, M. Kania, R.E. Dalbey, and MG.P. Page Crystallographic and biophysical analysis of a bacterial signal peptidase in complex with a lipopeptide-based inhibitor J Biol Chem 279 29 2004 30781 30790
62. M. Paetzel, A. Karla, N.C. Strynadka, and R.E. Dalbey Related signal peptidases Chem Rev 102 12 2002 4549 4580
63. P. Kulanthaivel, A.J. Kreuzman, M.A. Strege, M.D. Belvo, T.A. Smitka, and M. Clemens Novel lipoglycopeptides as inhibitors of bacterial signal peptidase I J Biol Chem 279 35 2004 36250 36258
64. I. Ciciliato, E. Corti, E. Sarubbi, S. Stefanelli, L. Gastaldo, and N. Montanini Antibiotics GE23077, novel inhibitors of bacterial RNA polymerase. Part I. Taxonomy, isolation and characterization J Antibiot (Tokyo) 57 3 2004 210 217
65. A. Marazzi, M. Kurz, S. Stefanelli, and L. Colombo Antibiotics GE23077, novel inhibitors of bacterial RNA polymerase. Part II. Structure elucidation J Antibiot (Tokyo) 58 4 2005 260 267
66. E. Sarubbi, F. Monti, E. Corti, A. Miele, and E. Selva Mode of action of the microbial metabolite GE23077, a novel potent and selective inhibitor of bacterial RNA polymerase Eur J Biochem 271 15 2004 3146 3154
67. R. Mariani, G. Granata, S.I. Maffioli, S. Serina, C. Brunati, and M. Sosio Antibiotics GE23077, novel inhibitors of bacterial RNA polymerase. Part 3. Chemical derivatization Bioorg Med Chem Lett. 15 16 2005 3748 3752
68. H. He Mannopeptimycins, a novel class of glycopeptide antibiotics active against Gram-positive bacteria Appl Microbiol Biotechnol 67 4 2005 444 452
69. H. He, R.T. Williamson, B. Shen, E.I. Graziani, H.Y. Yang, and S.M. Sakya Mannopeptimycins, novel antibacterial glycopeptides from Streptomyces hygroscopicus, LL-AC98 J Am Chem Soc 124 33 2002 9729 9736
70. De Vos SE, Kunstmann KP. Antibiotic AC98 and production. US Patent No. 3495004 1970.
71. R.G. Dushin, T.Z. Wang, P.E. Sum, H. He, A.G. Sutherland, and J.S. Ashcroft Hydrophobic acetal and ketal derivatives of mannopeptimycin-α and desmethylhexahydromannopeptimycin-α: semisynthetic glycopeptides with potent activity against Gram-positive bacteria J Med Chem 47 14 2004 3487 3490
72. W.J. Weiss, T. Murphy, E. Lenoy, and M. Young In vivo efficacy and pharmacokinetics of AC98-6446, a novel cyclic glycopeptide, in experimental infection models Antimicrob Agents Chemother 48 5 2004 1708 1712
73. P.J. Petersen, T.Z. Wang, R.G. Dushin, and P.A. Bradford Comparative in vitro activities of AC98-6446, a novel semisynthetic glycopeptide derivative of the natural product mannopeptimycin α, and other antimicrobial agents against gram-positive clinical isolates Antimicrob Agents Chemother 48 3 2004 739 746
74. K. Kimura, and T.D.H. Bugg Recent advances in antimicrobial nucleoside antibiotics targeting cell wall biosynthesis Nat Prod Rep 20 2 2003 252 273
75. L.A. McDonald, L.R. Barbieri, G.T. Carter, E. Lenoy, J. Lotvin, and P.J. Petersen Structures of the muraymycins, novel peptidoglycan biosynthesis inhibitors J Am Chem Soc 124 35 2002 10260 10261
76. L.A. McDonald, L.R. Barbieri, G.T. Carter, G. Kruppa, X. Feng, and J.A. Lotvin FTMS structure elucidation of natural products: application to muraymycin antibiotics using ESI multi-CHEF SORI-CID FTMS(n), the top-down/bottom-up approach, and HPLC ESI capillary-skimmer CID FTMS Anal Chem 75 11 2003 2730 2739
77. A. Yamashita, E. Norton, P.J. Petersen, B.A. Rasmussen, G. Singh, and Y. Yang Muraymycins, novel peptidoglycan biosynthesis inhibitors: synthesis and SAR of their analogues Bioorg Med Chem Lett 13 19 2003 3345 3350
78. Y.I. Lin, Z. Li, G.D. Francisco, L.A. McDonald, R.A. Davis, and G. Singh Muraymycins, novel peptidoglycan biosynthesis inhibitors: semisynthesis and SAR of their derivatives Bioorg Med Chem Lett 12 17 2002 2341 2344
79. M. Igarashi, N. Nakagawa, N. Doi, S. Hattori, H. Naganawa, and M. Hamada Caprazamycin B, a novel anti-tuberculosis antibiotic, from Streptomyces sp J Antibiot (Tokyo) 56 6 2003 580 583
80. M. Igarashi, Y. Takahashi, T. Shitara, H. Nakamura, H. Naganawa, and T. Miyake Caprazamycins, novel lipo-nucleoside antibiotics, from Streptomyces sp. II. Structure elucidation of caprazamycins J Antibiot (Tokyo) 58 5 2005 327 337
81. C. Dini, S. Didier-Laurent, N. Drochon, S. Feteanu, J.C. Guillot, and F. Monti Synthesis of sub-micromolar inhibitors of MraY by exploring the region originally occupied by the diazepanone ring in the liposidomycin structure Bioorg Med Chem Lett 12 8 2002 1209 1213
82. M.C. Bagley, J.W. Dale, E.A. Merritt, and X. Xiong Thiopeptide antibiotics Chem Rev 105 2 2005 685 714
83. J.E. Leet, W. Li, H.A. Ax, J.A. Matson, S. Huang, and R. Huang Nocathiacins, new thiazolyl peptide antibiotics from Nocardia sp. II. Isolation, characterization, and structure determination J Antibiot (Tokyo) 56 3 2003 232 242
84. W. Li, J.E. Leet, H.A. Ax, D.R. Gustavson, D.M. Brown, and L. Turner Nocathiacins, new thiazolyl peptide antibiotics from Nocardia sp. I. Taxonomy, fermentation and biological activities J Antibiot (Tokyo) 56 3 2003 226 231
85. T. Sasaki, T. Otani, H. Matsumoto, N. Unemi, M. Hamada, and T. Takeuchi MJ347-81F4 A & B, novel antibiotics from Amycolatopsis sp.: taxonomic characteristics, fermentation, and antimicrobial activity J Antibiot (Tokyo) 51 8 1998 715 721
86. M.J. Pucci, J.J. Bronson, J.F. Barrett, K.L. DenBleyker, L.F. Discotto, and J.C. Fung-Tomc Antimicrobial evaluation of nocathiacins, a thiazole peptide class of antibiotics Antimicrob Agents Chemother 48 10 2004 3697 3701
87. A. Regueiro-Ren, B.N. Naidu, X. Zheng, T.W. Hudyma, T.P. Connolly, and J.D. Matiskella Novel semi-synthetic nocathiacin antibiotics: synthesis and antibacterial activity of bis- and mono-O-alkylated derivatives Bioorg Med Chem Lett 514 1 2004 171 175
88. P. Hrnciar, Y. Ueda, S. Huang, J.E. Leet, and J.J. Bronson Synthesis of novel nocathiacin-class antibiotics. Condensation of glycolaldehyde with primary amides and tandem reductive amination of Amadori-rearranged 2-oxoethyl intermediates J Org Chem 67 25 2002 8789 8793
89. Sorensen D, McAlpine J, Piraee M, Farnet C, Zazopoulos E. Genome scanning technology reveals an antibacterial compound (ECO-0501) of a new structural class from the vancomycin-producer Amycolatopsis orientalis. In: Poster 720a: Proceedings of the 44th annual ICAAC conference, Washington, DC, November 2004. Available at http://www.ecopia.com/.
90. Alarco AM, Weiss K, Wu Q, Dimitriadou V, Perlas R, Concemi P et al. ECO-0501, a novel anti-Gram positive compound defining a new antibacterial structural class: preclinical evaluations. In: Poster F-719: Proceedings of the 44th annual ICAAC conference, Washington DC, November 2004. Available at http://www.ecopia.com/.
91. Alarco AM, Dimitriadou V, McAlpine J, Sorensen D, Zazopoulos E, Farnet C. ECO-0501, a novel anti-Gram-positive compound defining a new antibacterial structural class: mechanistic studies. In: Poster 720: Proceedings of the 44th annual ICAAC conference, Washington DC, November 2004. Available at http://www.ecopia.com/.
92. E. Zazopoulos, K. Huang, A. Staffa, W. Liu, B.O. Bachmann, and K. Nonaka A genomics-guided approach for discovering and expressing cryptic metabolic pathways Nat Biotechnol 21 2 2003 187 190
93. S. Pelzer, A. Vente, and A. Bechthold Novel natural compounds obtained by genome-based screening and genetic engineering Curr Opin Drug Discov Devel 8 2 2005 228 238
94. J.B. McAlpine, B.O. Bachmann, M. Piraee, S. Tremblay, A.M. Alarco, and E. Zazopoulos Microbial genomics as a guide to drug discovery and structural elucidation: ECO-02301, a novel antifungal agent, as an example J Nat Prod 68 4 2005 493 496
95. C.J. Thomson, E. Power, H. Ruebsamen-Waigmann, and H. Labischinski Antibacterial research and development in the 21st century - an industry perspective of the challenges Curr Opin Microbiol 7 5 2004 445 450
96. S. Donadio, L. Brandi, S. Serina, M. Sosio, and S. Stinchi Discovering novel antibacterial agents by high throughput screening Front Drug Des Discov 1 1 2005 3 16
97. R.A. Forsyth, R.J. Haselbeck, K.L. Ohlsen, R.T. Yamamoto, H. Xu, and J.D. Trawick A genome-wide strategy for the identification of essential genes in Staphylococcus aureus Mol Microbiol 43 6 2002 1387 1400
98. S.J. Projan New (and not so new) antibacterial targets - from where and when will the novel drugs come? Curr Opin Pharmacol 2 5 2002 513 522
99. F.L. Stahura, J.W. Godden, L. Xue, and J. Bajorath Distinguishing between natural products and synthetic molecules by descriptor Shannon entropy analysis and binary QSAR calculations J Chem Inf Comput Sci 40 5 2000 1245 1252
100. T. Henkel, R.M. Brunne, H. Müller, and F. Reichel Statistical investigation of structural complementarity of natural products and synthetic compounds Angew Chem Int Ed Engl 38 5 1999 643 647